Compare Procter & Gamble Co (PG) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Stryker Corporation — how do they compare? Procter & Gamble Co trades at $150.55 (market cap $343.34B), while Stryker Corporation trades at $276.77 (market cap $105.64B). The key difference: Procter & Gamble Co is far larger — about 3.3× Stryker Corporation's market cap, and Procter & Gamble Co pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Stryker Corporation for 20 Days on average.
| PG | SYK | |
|---|---|---|
Market Cap | $343.34B | $105.64B |
Volume | 8,662,344 | 1,918,844 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $388.35 |
52-Week Low | $138.10 | $269.75 |
Typical Hold Time | 131 Days | 20 Days |
Enterprise Value | $369.18B | $117.10B |
Dividend Yield | 2.95% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $150.59, up 1.47% today, with a bullish technical signal from moving averages and a consensus analyst price target of $160.13. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and strong profitability margins. Recent earnings have consistently beaten expectations, and the stock offers a dividend yield with a history of increases.
PG presents a stable investment with consistent earnings and dividend growth, supported by a robust balance sheet. Risks include premium valuation multiples and modest revenue growth outlook. Analyst sentiment is predominantly positive, with 53% buy ratings, but investors should monitor competitive pressures and economic sensitivity.
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
